arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Seres Therapeutics, Inc.

MCRB

$2.09 0.00 (0.00%) at close

14 Visible periods

30 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Good

Bullish

auto_awesome

Analytical Summary

Seres Therapeutics, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $18.5M

Dividend Yield —

Revenue Growth None

Op. Margin None

ROIC -167.9% ↗

FCF / Share $0.10 ↗

Trailing P/E 3.3x

Price / Book 0.5x

FCF Yield 4.7%

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

14-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$789.00K

— —

Net Income Profit after all expenses

$5.70M

↑ +4088.2% —

Operating Margin Operating profit as % of sales

-85.5%

↓ -92.1% —

FCF / Share Free cash flow per share

$0.10

↑ +100.5% —

Long-Term Debt Long-term obligations

$110.00M

↑ +120.0% —

trending_up

Bullish Indicators

Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

No bearish risks detected.

Health Breakdown

Profitability

100

Returns

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
Revenue Growth YoY (%)	—	N/M	1672.2% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+20803%)	-95.1% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1289%)	336.3% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+4104%)	-3.7% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-147%)	22.1% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+176%)	-11.9% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-249%)	47.5% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+493%)	—	—	—	—	—
EPS Growth YoY (%)	—	100.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	61.5% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-220.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	4088.2% Excellent ↑ Excellent Improving Year-over-year change in net income	N/M	54.5% Excellent ↑ Excellent Improving Year-over-year change in net income	-281.5% Weak ↓ Weak Declining Year-over-year change in net income	26.4% Excellent ↑ Excellent Improving Year-over-year change in net income	-26.8% Weak ↓ Weak Declining Year-over-year change in net income	29.0% Excellent ↑ Excellent Improving Year-over-year change in net income	-10.7% Weak ↑ Weak Improving Year-over-year change in net income	2.4% Caution ↑ Caution Improving Year-over-year change in net income	-67.2% Weak ↑ Weak Improving Year-over-year change in net income	-227.8% Weak Weak Year-over-year change in net income	-173.8% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	N/M	-39068.6% Weak ↓ Weak Declining Year-over-year change in free cash flow	55.7% Excellent Excellent Year-over-year change in free cash flow	-6935.5% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—	—
Revenue CAGR 3Y (%)	-52.0% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	—	56.1% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	-40.9% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	72.4% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	1.1% Weak Weak Compound annual revenue growth over 3 years	16.6% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—	—	—
Revenue CAGR 5Y (%)	-52.7% Weak ↓ Weak Declining Compound annual revenue growth over 5 years	—	34.9% Excellent ↑ Excellent Improving Compound annual revenue growth over 5 years	-26.0% Weak Weak Compound annual revenue growth over 5 years	46.1% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
Operating Margin (%) (%)	—	—	-85.5% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-670%)	—	-44.5% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-397%)	-265.3% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1869%)	-208.3% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1489%)	-354.8% Weak → Weak Stable Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2465%)	-284.7% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1998%)	-426.5% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2944%)	—	—	—	—
Profit Margin (%) (%)	—	—	-90.0% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-850%)	—	-45.2% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-477%)	-268.3% Weak → Weak Stable Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2336%)	-203.7% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1797%)	-350.0% Weak → Weak Stable Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3017%)	-278.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2420%)	-420.7% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3606%)	—	—	—	—
FCF Margin (%) (%)	109.6% Excellent Excellent Free cash flow as a percentage of revenue Optimal: > 10%	—	-99.2% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	—	-2.0% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-283.6% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-224.7% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-229.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-249.8% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—
FCF / Net Income (x)	0.15x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	-1095.51x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.10x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.04x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.06x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.10x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.65x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
Return on Invested Capital (%)	-167.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-695.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-131.0% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-320.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-38.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-34.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	243.4% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	164.9% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-119.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-55.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-21.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	44.6% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	43.0% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-68.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-86.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-30.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-70.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-18.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-25.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-54.3% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-83.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-48.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-34.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-25.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-12.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	12.9% Fair ↓ Fair Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-14%)	1.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-93%)	253.5% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1590%)	—	-49.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-432%)	-51.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-440%)	145.4% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+870%)	205.9% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1273%)	-147.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1082%)	-69.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-560%)	-26.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-278%)	62.5% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+317%)	54.9% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+266%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
Debt to Equity (x)	—	—	-2.45x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-509%)	4.64x Weak ↑ Weak Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+673%)	—	0.14x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-76%)	-0.52x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-186%)	—	—	—	—	—	—	—
Interest Coverage (x)	—	—	-8.20x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-40.95x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-22.16x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-30.14x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-143.18x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	-91395.00x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—
Net Debt (USD)	$-45.77M	$-30.79M	$-17.96M	$-113.03M	$-180.00M	$-91.05M	$-40.13M	$-85.82M	$-36.09M	$-54.54M	$-73.93M	$-114.19M	$-1.65M	$-6.21M
Debt / EBITDA (x)	—	—	-1.08x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.21x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	-0.31x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.39x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
Revenue per Share (USD)	$0.09	$0.00	$0.05	$0.00	$0.08	—	—	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$0.64	$0.00	$-0.04	$-0.12	$-0.04	—	—	—	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$0.10	$-19.18	$-0.05	$-0.11	$-0.00	—	—	—	—	—	—	—	—	—
Book Value per Share (USD)	$4.63	$1.59	$-0.02	$0.00	$0.07	$0.10	$-0.03	$-0.06	$0.07	$0.16	$0.26	$-0.19	—	—
Tangible Book Value per Share (USD)	$4.63	$1.59	$-0.02	$0.00	$0.07	$0.10	$-0.03	$-0.06	$0.07	$0.16	$0.26	$-0.19	—	—
Basic Weighted Avg Shares (shares)	8.86M	7.77M	2.56B	2.16B	1.83B	—	—	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
Working Capital (USD)	$30.05M	$-2.55M	$76.75M	$109.17M	$221.37M	$222.36M	$54.20M	$50.62M	$123.45M	$167.91M	$196.69M	$109.14M	—	—
LT Debt (USD)	—	—	$110.00M	$50.00M	—	$25.00M	$25.00M	—	—	—	—	—	—	—
Total Equity (USD)	$44.22M	$13.78M	$-44.86M	$10.78M	$131.51M	$174.75M	$-48.32M	$-48.05M	$60.70M	$132.63M	$205.39M	$-26.72M	$-11.12M	$-4.35M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
Sales/Revenue/Turnover (USD)	$789.00K	$0.00	$126.33M	$7.13M	$144.93M	$33.22M	$34.51M	$28.27M	$32.10M	$21.77M	$0.00	—	—	—
Depreciation Expense (USD)	$4.13M	$5.47M	$6.24M	$6.63M	$5.95M	$6.58M	$7.60M	$7.86M	$7.26M	$4.21M	$728.00K	$190.00K	$88.00K	—
Net Income, GAAP (USD)	$5.70M	$136.00K	$-113.72M	$-250.16M	$-65.58M	$-89.13M	$-70.28M	$-98.94M	$-89.38M	$-91.58M	$-54.78M	$-16.71M	$-6.10M	—
Operating Cash Flow (USD)	$1.12M	$-148.61M	$-117.35M	$-228.82M	$6.69M	$-93.61M	$-76.52M	$-62.85M	$-75.52M	—	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 14 years · 52 quarters

Seres Therapeutics, Inc.

Analytical Summary

14-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare MCRB with peers